Retatrutide 40mg

Buy Retatrutide 40mg is a research-focused product centred on retatrutide, an investigational triple hormone receptor agonist being studied for its effects on metabolic pathways. Also known as LY3437943, retatrutide activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

Retatrutide is currently being evaluated in Phase 3 clinical research. It has not been approved by the FDA or any other regulatory agency for general public use.

Product Information

Product Name	Retatrutide 40mg
Active Compound	Retatrutide
Alternative Name	LY3437943
Strength	40mg
Product Type	Investigational research compound
Target Receptors	GIP, GLP-1 and glucagon
Research Area	Metabolic and obesity research
Development Stage	Phase 3 clinical development
Regulatory Status	Not approved for general public use
Intended Purpose	Scientific and laboratory research

What Is Retatrutide?

Retatrutide is an investigational molecule developed by Eli Lilly. Unlike medicines that target only one or two metabolic hormone pathways, retatrutide activates GIP, GLP-1 and glucagon receptors.

This three-pathway activity is why retatrutide is commonly described as a triple agonist.

The term “GLP-3” is sometimes used informally online, but Lilly notes that this is not a scientifically accurate classification. Retatrutide is more appropriately described as a GIP, GLP-1 and glucagon triple receptor agonist.

Retatrutide 40mg Strength

The 40mg specification identifies the stated amount of retatrutide associated with this research product. It should not be interpreted as a recommended clinical dose.

Clinical trials of retatrutide have evaluated specific investigational dosing regimens under controlled research conditions. For example, Lilly’s Phase 3 TRIUMPH-2 study evaluated 4mg, 9mg and 12mg target doses. These clinical trial doses should not be used to determine how a separate 40mg research product should be used.

How Retatrutide Works

Retatrutide is being investigated because of its activity across three hormone receptors.

GIP

Glucose-dependent insulinotropic polypeptide is a metabolic hormone involved in glucose and nutrient regulation. Retatrutide activates the GIP receptor as part of its triple-receptor mechanism.

GLP-1

GLP-1 is involved in glucose regulation, appetite signalling and gastrointestinal processes. GLP-1 receptor activity is an important area of metabolic research.

Glucagon

Glucagon plays an important role in maintaining glucose availability and regulating energy metabolism. Retatrutide’s glucagon receptor activity distinguishes it from traditional GLP-1 receptor agonists.

The combination of these pathways is a major reason retatrutide has attracted interest in metabolic research.

Retatrutide Research

Retatrutide is being studied across several areas of metabolic and obesity research.

Current clinical development has included research involving:

• Obesity and overweight
• Type 2 diabetes
• Weight-related metabolic conditions
• Cardiovascular outcomes
• Obstructive sleep apnea
• Knee osteoarthritis
• Chronic low back pain
• Metabolic dysfunction-associated steatotic liver disease

These are research areas being evaluated in clinical trials. They should not be interpreted as approved indications for Retatrutide 40mg.

Clinical Development

Retatrutide has progressed into Phase 3 clinical development.

In July 2026, Lilly reported results from the TRIUMPH-2 and TRIUMPH-3 Phase 3 studies. In TRIUMPH-2, participants with obesity or overweight and type 2 diabetes receiving the 12mg target dose experienced an average 20.8% weight reduction at 80 weeks. These results came from a controlled clinical trial and do not establish the safety or effectiveness of independently sourced retatrutide products.

Lilly has stated that it planned to submit a Biologics License Application for retatrutide in the United States in the first quarter of 2027. Until regulatory approval occurs, retatrutide remains investigational.

Research Product Quality

For research materials, clear product identification is important.

Product documentation should identify the compound, stated strength, formulation and appropriate storage requirements. Research users should also review available analytical documentation and manufacturer information before working with any research material.

A stated 40mg strength does not establish that a product is clinically approved, sterile, suitable for injection or appropriate for human administration.

Important Regulatory Information

Retatrutide is not currently FDA-approved. Lilly states that retatrutide is not available for public use and that it is legally available only through Lilly-sponsored clinical trials. Lilly also warns that products claiming to contain retatrutide outside clinical trials may contain unknown ingredients, contaminants, impurities, or incorrect amounts of active ingredient.

The FDA has also stated that retatrutide cannot be used in compounding under federal law and has taken enforcement action involving companies marketing unapproved retatrutide products.

For this reason, Retatrutide 40mg should be presented according to its actual regulatory status and should not be marketed as an approved weight-loss treatment.

Buy Retatrutide 40mg Online

Retatrutide 40mg may appear in searches related to retatrutide research, LY3437943, triple agonist research and metabolic research.

When evaluating research products, consider the stated compound identity, product strength, documentation, testing information, storage requirements and applicable regulations.

Search terms such as Retatrutide 40mg, retatrutide research, LY3437943 research, and retatrutide research compound can help users find information about this investigational compound without presenting it as an approved medicine.

Product Summary

Retatrutide 40mg is a research-focused product centred on retatrutide, also known as LY3437943. Retatrutide is an investigational GIP, GLP-1 and glucagon triple receptor agonist currently undergoing clinical development.

The 40mg specification identifies the stated product strength and should not be interpreted as a clinical dosing recommendation. Retatrutide remains investigational and is not currently approved for general public use.

Retatrutide 40mg | LY3437943 Research Compound

Explore Retatrutide 40mg, a research-focused product centred on retatrutide, LY3437943 and GIP, GLP-1 and glucagon receptor research.

Retatrutide 40mg

Retatrutide 40mg, Retatrutide research, LY3437943, LY3437943 research, retatrutide peptide, retatrutide research compound, triple agonist research, GIP GLP-1 glucagon, metabolic research

Retatrutide 40mg, Retatrutide, LY3437943, Retatrutide Research, Retatrutide Research Compound, Triple Agonist, GIP GLP-1 Glucagon, Metabolic Research, Peptide Research, Research Compound